Positively Aware HIV Drug Guide: Cabenuva

Cabenuva

cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension CAB LA/RPV LA

Recommended as optimization therapy for people with undetectable HIV viral load for at least 3 months on treatment
Long-Acting Regimen

Standard Dose

Optional one-monthly oral lead-in with food, then two intramuscular gluteal (butt) injections once every two months with or without food. Consists of one injection of long-acting cabotegravir and one injection of long-acting rilpivirine. For switching when suppressed, no history of treatment failure, and no resistance to components. Monthly injections optional. See doses on Cabenuva drug page in the POSITIVELY AWARE HIV Drug Guide.
  • See Edurant; cabotegravir is not available separately 
  • See package insert for more complete information on potential side effects and interactions.

Manufacturer

ViiV Healthcare
viivhealthcare.com; cabenuva.com
(877) 844-8872

AWP

28-day oral lead-in provided at no cost
Loading dose (600 mg/900 mg): $7,306.20
Maintenance dose (400 mg/600 mg): $4,870.80/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments